Direct Oral Anticoagulants (DOACs) versus LMWH +/- Warfarin for VTE in Cancer: A Randomized Effectiveness Trial (CANVAS Trial)

Protocol No
AFT-28-CANVAS
Principal Investigator
Lisa Baumann Kreuziger
Phase
III
Summary
The purpose of this study is to compare the benefits, harms, and burdens of two different approaches to anticoagulation therapy in patients with cancer: -anticoagulation therapy with a low molecular weight heparin (LMWH) alone or followed by warfarin (the usual approach, described above). versus -anticoagulation therapy with a direct oral anticoagulant (DOAC) (called the study approach in this form). All of the medications used in this study have already been FDA-approved to treat blood clots. Therapy with a DOAC is already FDA-approved for use as anticoagulation therapy, but DOACs have not been studied extensively in patients with cancer. This study will allow the researchers to gather information about whether anticoagulation therapy with a LMWH alone or followed by warfarin is better, the same, or worse than anticoagulation therapy with a DOAC in patients with cancer.
Description
Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer (CANVAS)
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL
Share This: